Aytu BioPharma Names Ryan Selhorn as CFO

Dow Jones11-14

By Stephen Nakrosis

Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11.

He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1.

Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as VP, finance, consumer healthcare division.

Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said.

Selhorn will receive an annual base salary of $400,000.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 13, 2024 18:53 ET (23:53 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483864158?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 07:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483864158","market":"sh","top_or_hot":-1,"title":"Aytu BioPharma Names Ryan Selhorn as CFO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11. \n</p>\n<p>\n  He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1. \n</p>\n<p>\n  Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as <a href=\"https://laohu8.com/S/VP..UK\">VP</a>, finance, consumer healthcare division. \n</p>\n<p>\n  Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said. \n</p>\n<p>\n  Selhorn will receive an annual base salary of $400,000. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 13, 2024 18:53 ET (23:53 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aytu BioPharma Names Ryan Selhorn as CFO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAytu BioPharma Names Ryan Selhorn as CFO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 07:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Stephen Nakrosis \n\n\n \n\n\n  Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11. \n\n\n  He succeeds Mark Oki ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2483864158","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483864158","pubTimestamp":1731541980,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11.He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1.Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as VP, finance, consumer healthcare division.Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said.Selhorn will receive an annual base salary of $400,000.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","AYTU":"Aytu BioScience, Inc."},"translate_title":"Aytu BioPharma任命Ryan Selhorn为首席财务官","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AYTU":0.9},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Aytu BioPharma said Ryan Selhorn has been named as the company's chief financial officer, treasurer and corporate secretary, effective Nov. 11. \n\n\n  He succeeds Mark Oki as CFO. Oki will continue to consult for the company through Dec. 1. \n\n\n  Prior to being named CFO, Selhorn served as EVP, finance and business optimization, since November 2022, the company said. Before that, he was SVP, finance and operations, consumer healthcare division, and also served as VP, finance, consumer healthcare division. \n\n\n  Selhorn also served as VP and CFO at Innovus Pharmaceuticals, and as CFO and chief accounting officer of Signature Analytics, Aytu said. \n\n\n  Selhorn will receive an annual base salary of $400,000. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 18:53 ET (23:53 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483864158"}